quartr
PHO: Q2 2026 delivered double-digit revenue growth and expanded diagnostics capabilities through acquisition
Q2 2026 saw 11% constant currency revenue growth for Hexvix/Cysview, driven by strong North American and European performance, and the strategic acquisition of Vesica Health. Adjusted EBITDA margin remained robust at 19%, while regulatory and technological advances are set to expand future market o…